Government
Every published round Innovation Investment Fund (IIF) took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Innovation Investment Fund (IIF) has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
This is a stake in the fund itself, money that the fund's manager invests, not a stake in the fund manager.
Companies Innovation Investment Fund (IIF) has backed that another company then bought. An exit for the holding, not a deal Innovation Investment Fund (IIF) did.
Stories naming Innovation Investment Fund (IIF). Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaxxas has exclusively licensed UT Austin's HexaPro spike protein for a needle-free COVID-19 vaccine patch, backed by an NIH license, with a Phase 1 trial planned this year; background notes its founding backers.
Vaxxas has received a US$22 million (A$30.6 million) US government BARDA award to advance its needle-free vaccine patch for pandemic use; earlier financing led by OneVentures with Brandon Capital is recalled.
GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.